![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Scheen A.J.
Publisher: Adis International
ISSN: 1175-3277
Source: American Journal of Cardiovascular Drugs, Vol.10, Iss.5, 2010-10, pp. : 321-334
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :